Immunome, Inc. · 3 months ago
Vice President/Executive Director, Medical Affairs
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class therapies for cancer patients. The Vice President/Executive Director, Medical Affairs will lead Medical Science Liaisons, Patient Advocacy, and Medical Information, focusing on building external presence and driving stakeholder engagement.
BiopharmaBiotechnologyMedicalPharmaceutical
Responsibilities
Build, train, and lead the MSL team
Develop strategic field plans and educational materials
Engage healthcare professionals and synthesize external insights
Define and track performance metrics
Lead relationships with sarcoma patient advocacy groups (PAGs)
Develop and execute a strategic engagement plan
Bring patient perspectives into internal planning and activities
Oversee medical information systems and response materials
Select and manage external partners
Ensure proper handling of adverse events and product inquiries
Stay current on sarcoma research and therapeutic trends
Collaborate across departments and represent the patient and HCP voice internally
Maintain compliance with industry regulations
Manage function-specific budgets and KPIs
Qualification
Required
Advanced scientific degree (PhD, PharmD, MD, or DO)
12+ years in Medical Affairs, with oncology experience
Proven leadership of field-based teams and product launches
Comfortable building and scaling new functions
Proven track-record of effective leadership of field teams
Experience with product launches, especially in a highly competitive environment
Comprehensive understanding of US regulatory, legal, and compliance guidelines in the pharmaceutical industry, with a commitment to high ethical standards and scientific integrity
Excellent communication, presentation, and time and project management skills
Preferred
Experience working directly within other functions (e.g., Scientific Communication, Operations, Clinical Development) is highly desirable
Company
Immunome, Inc.
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients.
Funding
Current Stage
Public CompanyTotal Funding
$998.85MKey Investors
JPEO-CBRNDU.S. Department of DefenseRobin Hood Ventures
2025-12-16Post Ipo Equity· $400M
2025-01-29Post Ipo Equity· $150M
2024-02-13Post Ipo Equity· $230M
Recent News
2026-01-09
BioWorld Financial Watch
2025-12-19
Company data provided by crunchbase